Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fianostics is an Austrian diagnostics company that develops and manufactures high-sensitivity fluorescence immunoassays and related diagnostic workflows. Its core technology is the FluoBolt platform, which uses metal-enhanced fluorescence and plasmonic substrates to improve assay sensitivity while remaining compatible with standard 96-well microtiter plate readers. The company markets research-use and in vitro diagnostic assay kits and also operates INOOlab, a finger-blood-based testing workflow for personalized preventive diagnostics. Publicly visible products include SARS-CoV-2 antibody assays as well as biomarker assays such as Asporin and Klotho. Fianostics appears to be a private, active healthcare company focused on immunoassay technology, biomarker detection, and decentralized sample collection linked to certified laboratory testing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Fianostics.